Molecular Test Assessments

Molecular Test Assessments are comprehensive health technology assessments of molecular tests across a range of conditions and applications. Each report provides a clear, objective view of the science behind a specific molecular test, the clinical evidence supporting the test, the manufacturer, an explanation of how the test is used in clinical practice, and appropriate patient selection criteria.

These reports include the Hayes Rating to indicate the overall strength and direction of the body of evidence for the molecular test. Molecular Test Assessments provide evidence-based support for the development of coverage policy, utilization management, and evidence-based clinical practices. Reports are reviewed annually up to 5 years post publication to determine if there is new literature or evidence that would impact a change in rating and warrant an updated report.

PancraGEN (Interpace Diagnostics)

This report evaluates the analytical validity, clinical validity, and clinical utility of the PancraGEN (Interpace Diagnostics) test.

PancraGEN (Interpace Diagnostics)

This report evaluates the analytical validity, clinical validity, and clinical utility of the PancraGEN (Interpace Diagnostics) test.

DCISionRT (Prelude Corp.)

This report evaluates the analytical validity, clinical validity, and clinical utility of the DCISionRT (Prelude Corp.) test.

clonoSEQ (Adaptive Biotechnologies)

This report evaluates the analytical validity, clinical validity, and clinical utility of the clonoSEQ test (Adaptive Biotechnologies) specific to U.S. Food and Drug Administration (FDA)-cleared intended use.